BCL2L12 and ovarian carcinoma: To determine the clinical relevance of BCL2L12 exon 3 skipping in ovarian cancer, we analyzed the expression of BCL2L12-L (exon 3 inclusion) and BCL2L12-S (exon 3 skipping) in the TCGA ovarian cancer database and found that BCL2L12-L was significantly increased whereas BCL2L12-S was decreased in SOC (Fig. 6k, l).